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Guidelines and Guidance
The mechanisms of immune protection against human TB, a disease that causes 2 million deaths world-wide each year, are not fully known. T cell 
immunity is critical for protection [1,2]; therefore, the 
current TB vaccine, bacille Calmette-Guérin (BCG), and 
most new vaccines under development aim to induce this 
immunity. Most of these developmental vaccines  [1–4] 
are designed to boost pre-existing immunity induced by 
BCG; however, some candidates aim to ultimately replace 
BCG as the priming vaccine. Following phase I/IIa trials 
of the vaccines, safety and immunogenicity results will 
be critical to decide which vaccine candidates should 
move into efficacy trials. For this choice, the ability to 
compare immunogenicity would be an important asset. 
Potential comparisons are confounded by variation in 
individual laboratory approaches, logistics, and the diverse 
populations studied in vaccine trials. Some comparison 
may be achieved by harmonisation of assays (see below); 
however, even then, antigen components of vaccines and 
therefore antigens in assays may differ. Further, the desired 
character of induced immunity may differ according 
to vaccine candidate, making choice of an assay to be 
harmonised difficult.
To tackle this problem, the WHO Initiative for Vaccine 
Research sponsored three meetings of experts representing 
current TB vaccine development efforts to discuss the 
requirements for and challenges in harmonising assays for 
new TB vaccine trials. The primary focus was on phase I 
and IIa trials; other principles may apply to phase IIb and 
III trials because of their larger sample sizes and because 
resources in settings of these trials may differ. In this article, 
we describe advantages and disadvantages of multiple assay 
approaches and make recommendations for using specific 
assay approaches in phase I/IIa trials. 
T Cell Assays that May Be Used in New TB Vaccine 
Trials
Some T cell assays use whole blood, while others use isolated 
peripheral blood mononuclear cells (PBMCs). PBMCs may 
either be used fresh, or after cryopreservation. Assays may 
have relatively short (less than 24 hours), intermediate 
(one to three days), or longer (five to seven days) periods 
of incubation. Each assay approach may have distinct 
advantages, as summarised in Table S1.
The choice of assay system may be guided by the aspect of 
T cell immunity to be measured; for example, as described 
in Table S1, longer-term assays may be better for measuring 
central memory T cell responses thought to be critical for 
long-term protection induced by vaccines [5,6,7]. Choice is 
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Summary Points
?? ?????????????????????????????????????????????????????????
under development. 
?? ????????????????????????????????? ?????????????????????
different candidates would be an important asset. 
?? ???? ????? ?????? ?????????????????????????????????????????
Research  sponsored three meetings of experts to discuss 
assay harmonization for new tuberculosis vaccine trials. 
?? ???????????????????????????????????????????? ???????????????
assay approaches and make specific recommendations for 
phase I/IIa trials. These include introducing a single and simple 
harmonised assay for all trials.
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often dictated by what is practical in the setting; for example, 
if incubation of whole blood or PBMC isolation early after 
blood collection cannot be accomplished readily, it may 
be wiser to perform longer-term diluted whole-blood or 
PBMC assays, to minimise a potentially significant effect of 
processing delay on assay outcome (see below). Blood volume 
restrictions in infants, compared with adults, may further 
dictate assay choice (see below).
T cell assays that are widely used and that appear practical 
in phase I/IIa trials include five to seven-day whole-blood 
or PBMC assays of cytokine production and proliferation, 
overnight or 48-hour enzyme-linked immunosorbent spot 
(ELISPOT) assays (see protocol in Text S1), and intracellular 
cytokine assays after six to 18-hour incubation of whole blood 
or PBMC with specific antigens (see protocol in Text S2). A 
discussion of these assays, including specific advantages and 
disadvantages of each and experience in TB vaccinology, may 
be found in Text S3. Text S3 also includes a discussion of less 
frequently used assays, such as cytotoxic cell degranulation 
assays, mycobacterial inhibition assays, and tetramer assays. 
At this stage, comparisons of assay outcomes among different 
new TB vaccine trials are not possible, mainly due to the 
diversity of technical approaches, even if the same basic assay 
system is used. 
Time to Incubation of Whole Blood, or to PBMC 
Isolation 
Delaying incubation of whole blood, or delaying isolation 
of PBMCs after blood collection, may affect assay outcomes 
(see Text S3 for more detail). Overall, available evidence 
suggests that sub-optimal outcomes of shorter-term assays are 
likely when delays occur from the time of blood collection to 
incubation, or to PBMC isolation and cryopreservation for 
later incubation. The panel therefore recommended that 
until further evidence becomes available, PBMCs for later 
ELISPOT and short-term intracellular cytokine assays be 
isolated as soon as possible after blood collection and never 
more than eight hours after collection, preferably at the same 
time point after collection in all participants of a specific 
study. The same principles apply to short-term, undiluted 
whole-blood intracellular cytokine assays; incubation later 
than two hours after collection should not be considered. In 
contrast, longer-term assays, such as a six to seven-day whole-
blood assay, appear to be less affected by delays in incubation 
(H. M. Dockrell, personal communication); we hypothesise 
that these assays measure expansion of specific T cells, and 
are therefore less affected than shorter-term assays that 
measure direct ex vivo function quantitatively. 
Recent Advances in PBMC Cryopreservation and 
Thawing
Multiple variables in the PBMC isolation, cryopreservation, 
and thawing process affect ultimate recovery of viable, 
functional cells ([8]; Smith and Dockrell, unpublished 
data). Although most labs use very similar procedures, 
conflicting results regarding fine details such as freezing 
media composition have emerged (T. Kollmann, personal 
communication; [8]). However, most researchers now agree 
that assay results of increased quality may be obtained when 
PBMCs are “rested” for at least four hours after thawing, 
prior to adding antigens for functional assays. In shorter-term 
assays, this procedure may decrease assay background and 
increase functional response [9,10].
Harmonisation, Standardisation, and Validation of 
Assays
“Harmonisation” refers to a consensus in assay standard 
operating procedures for multiple testing sites. 
“Standardisation” comprises all measures necessary to 
obtain comparable results, in terms of both time and place. 
Optimal standardisation will result in comparable results 
when a test is performed at different times and by different 
technicians in different laboratories. To achieve such 
results, standardised materials, reagents, and equipment are 
important. “Validation” refers to a detailed characterisation 
of assay performance. Typical validation characteristics 
include accuracy, repeatability, specificity, detection limit, 
quantitation limit, linearity, and range. Regulatory authorities 
require that investigators introduce a validated assay as the 
primary immunological outcome in new vaccine trials, if the 
data are intended to be used for licensure. “Qualification” 
is a term sometimes used to describe partial validation, and 
refers to an experimental protocol that demonstrates that an 
accepted method will provide meaningful data, given specific 
conditions and samples. 
Currently, a number of different harmonised standard 
operating procedures have been prepared within different 
multi-national consortia or projects such as the European 
Union–supported TB-VAC and MUVAPRED (Mucosal 
Vaccines for Poverty Related Diseases) initiatives, Bill & 
Melinda Gates Foundation Grand Challenges in Global 
Health projects such as GC6-74 (“Biomarkers for TB”), 
and EUROVAC. All the assays discussed here are used to 
some extent by these large consortia, and in some cases 
the differences between protocols are relatively minor. It 
should therefore be relatively simple to get stakeholders 
together and produce harmonised protocols, particularly 
as small differences in protocols may make a major 
difference in the outcome of certain assays such as the 
ELISPOT. The panel therefore recommended that efforts 
at harmonisation and standardisation of assays should be 
supported. We recommend starting the discussion process 
with harmonisation and standardisation of the short-term 
ELISPOT assay and the longer-term whole-blood interferon 
(IFN)-γ assay. Further, standardisation of positive controls 
and detection methods should be attempted. (See Text S3 for 
more information.) 
A Single, Common Assay in New Vaccine Trials
It is likely that investigators and sponsors will continue to 
introduce their “favourite” assays in new TB vaccine trials. 
However, a single, harmonised assay common to all vaccine 
trials would be ideal to allow comparison of immunogenicity 
results between different vaccine candidates, and the use 
of such an assay is strongly recommended by members of 
this expert panel. Ideally, such an assay should be widely 
implementable, even at remote field sites, while delivering 
informative results. The panel judged that the seven-day whole-
blood IFN-γ assay best meets these criteria and recommended 
that it be introduced into all new TB vaccine trials. Excellent 
performance of this assay has been demonstrated in multiple 
large clinical studies. Additionally, GC6-74 (“Biomarkers for 
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TB”) has standardised this method to screen new TB antigens 
at field sites. A harmonised protocol has been developed (Text 
S4). It will also be important to standardise reagents and the 
equipment that measures cytokine levels.
“Vaccine Take” and Immune Correlates/Surrogates of 
Protection against TB
All current assays described here use the magnitude and, 
to some extent, the qualitative character of the immune 
response to measure “vaccine take”. Without a complete 
knowledge of immune correlates of vaccination-induced 
protection against TB, all assays may be described as vaccine 
take assays. Regardless, the current assays focus on T cell 
immunity, particularly IFN-γ production, which is thought 
to be important for protection. Because emerging evidence 
suggests that IFN-γ production alone is not necessarily an 
immune correlate of vaccination-induced protection against 
TB (W. A. Hanekom, unpublished observations; [11]) it 
is important to define these correlates in complementary 
projects. Multiple ongoing projects aim to define immune 
correlates of protection, which may ultimately be validated 
as surrogates of protection in phase IIb/III trials of effective 
TB vaccines. Until these correlates/surrogates are available, 
it would be extremely useful to also store blood products in 
a manner that is efficient and that would allow an excellent 
functional yield of cells or products when thawed at a later 
stage. These blood products would then be available to 
measure newly described immune correlates/surrogates 
of protection, in retrospective studies or for application of 
newer technologies.
The panel therefore recommended that PBMCs should be 
stored for possible future use in new TB vaccine trials. Various 
protocols for PBMC isolation, cryopreservation, and thawing 
are available [8,10]. It should be noted that the shortest 
possible interval from blood collection until cryopreservation 
is desirable (see above), but because this may not be practical, 
it may be best to standardise the time from blood collection 
to PBMC isolation. 
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